MDMA-assisted psychotherapy for treatment of post-traumatic stress disorder: a systematic review with meta-analysis

Introduction

Post-traumatic stress disorder (PTSD) is a debilitating condition marked by avoidance, hypervigilance and re-experiencing of traumatic events, often complicated by comorbid anxiety, depression and substance use. Existing pharmacologic options have modest efficacy and many patients do not respond adequately; selective serotonin reuptake inhibitors (SSRIs) and venlafaxine are guideline-recommended but require chronic daily dosing and show variable withdrawal rates. MDMA (3,4-methylenedioxymethamphetamine) has pharmacologic effects that may facilitate psychotherapy—elevating mood, increasing interpersonal bonding and reducing amygdala activity—suggesting it could enable patients to process trauma with less acute distress. Regulatory barriers historically limited research, but recent Phase II and a Phase III trial have expanded the evidence base after FDA breakthrough designation in 2017. Smith and colleagues set out to systematically review clinical trials of MDMA-assisted psychotherapy for PTSD and to pool quantitative outcomes where feasible. The review focused on change in Clinician-Administered PTSD Scale (CAPS) scores, the proportion achieving clinically significant CAPS reductions, and the proportion no longer meeting CAPS diagnostic thresholds, with additional narrative synthesis of crossover/open-label phases, adverse events and longer-term follow-up data. The aim was to clarify efficacy, safety and durability of effects, and to identify limitations in the existing literature.